All In Biotech

BLA 761142 · Viela Bio

Uplizna

Inebilizumab-Cdon · Injection · CD19-directed Cytolytic Antibody

NovelBreakthrough therapyOrphan

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 11, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

28

7 Phase 3, 11 recruiting

FAERS reports

858

625 serious, 53 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 21, 2026.

UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of: Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 1.2 Immunoglobulin G4-Related Disease (IgG4-RD) UPLIZNA is indicated for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients. 1.3 Generalized Myasthenia Gravis (gMG) UPLIZNA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.

Mechanism: The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • UPLIZNA · INEBILIZUMAB-CDON 100MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Inebilizumab" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neuromyelitis optica spectrum disorder130
  • off label use76
  • headache50
  • urinary tract infection44
  • fatigue39
  • nausea38
  • myasthenia gravis37
  • pneumonia36
  • covid-1932
  • pain31
  • arthralgia25
  • death23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202021
202179
202222
202350
2024143
2025161
2026382

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Uplizna (Inebilizumab-Cdon)

2024 spending

$15.0M

Beneficiaries

64

100 claims

Per beneficiary

$234,900

$4,668.82 per unit

View as table
YearSpending
2020$0
2021$0
2022$4,456,141
2023$12,977,952
2024$15,033,602

Part B: Uplizna (Inebilizumab-Cdon) · HCPCS J1823

2024 spending

$52.8M

Beneficiaries

201

610 claims

Per beneficiary

$262,865

2024 ASP limit $478.82 per unit

View as table
YearSpending
2020$0
2021$13,521,358
2022$27,573,167
2023$38,276,760
2024$52,835,927

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Viela Bio

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.